The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) injected periodically have been shown to not increase and, for some members of this class, decrease the risk of cardiovascular events. The cardiovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650) is unknown. Here, we randomly assigned patients with type 2 diabetes with, or at risk for, atherosclerotic cardiovascular disease (ASCVD) to receive ITCA 650 or placebo to assess cardiovascular safety in a pre-approval trial ( NCT01455896 ). The primary outcome was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina. On the basis of 2008 guidance from the US Food and Drug Administration, a non-inferiority margin of 1.8 for the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was used. We randomized 4,156 patients (2,075 assigned to receive ITCA 650 and 2,081 assigned to receive placebo) who were followed for a median of 16 months. The primary outcome occurred in 4.6% (95/2,075) of patients in the ITCA 650 group and 3.8% (79/2,081) of patients in the placebo group, meeting the pre-specified non-inferiority criterion (HR = 1.21, 95% CI, 0.90-1.63, P non-inferiority = 0.004). Serious adverse events were similar between the two groups. Adverse events were more frequent in the ITCA 650 group (72%, 1,491/2,074) than in the placebo group (63.9%, 1,325/2,070), mainly due to an increase in gastr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a CVOT of an osmotic minipump delivering exenatide subcutaneously (ITCA 650) over 3 -6 months, ITCA 650 had a neutral effect on MACE compared with placebo over 16 months (248).”
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationPrevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Self-citationLachin, J. M., & Foulkes, M. A. (1986) · Biometrics · doi:10.2307/2531201 · Cited by 400
Research works printed but not linked: 1
- Rosenstock, J. et al. Superior efficacy of ITCA 650 vs sitagliptin in uncontrolled type 2 diabetes on metformin: the FREEDOM 2 randomized, double-blind, 1-year study. Diabetes 65, 183–1 (2016).
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“In a CVOT of an osmotic minipump delivering exenatide subcutaneously (ITCA 650) over 3–6 months, ITCA 650 had a neutral effect on MACE compared with placebo over 16 months (248).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“In a CVOT of an osmotic minipump delivering exenatide subcutaneously (ITCA 650) over 3–6 months, ITCA 650 had a neutral effect on MACE compared with placebo over 16 months [248].”
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359
Self-citationRivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K. M., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 181
“Ten RCTs [2,4-7, 14-18 14-18] reported MACE as the primary Nine RCTs [2,4-6,9,14-18] were done exclusively on patients with T2DM, and two [7,8] studies excluded patients with T2DM.”
Background
Metadata
- Authors
- Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Intarcia Therapeutics (United States) (US)
- Corresponding author
- Ruff, Christian T.
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-12-06
- Volume
- 28
- Issue
- 1
- Pages
- 89-95
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4200333560
- Cited by
- 102
- References
- 17
- Citations by year
- 2026: 19 · 2025: 31 · 2024: 21 · 2023: 17 · 2022: 13 · 2021: 1
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- exenatide, subcutaneous infusion, type 2 diabetes, cardiovascular safety, atherosclerotic cardiovascular disease, non-inferiority, myocardial infarction, stroke, cardiovascular mortality, gastrointestinal adverse effects, GLP-1 receptor agonists, insulin pump therapy, serious adverse events
- MeSH terms
- Exenatide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Treatment Outcome, Infusions, Subcutaneous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41591-021-01584-3
- The paper
- Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022). Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01584-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.